Lifecore Biomedical, Inc. Common Stock
LFCRLifecore Biomedical, Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of advanced biomaterials, including hyaluronic acid-based products used in medical and aesthetic applications. Founded in 1983, the company serves sectors such as ophthalmology, orthopedics, and aesthetics, providing products that support tissue repair and regeneration.
Company News
Lifecore Biomedical's compensation committee approved equity inducement grants on January 14, 2026, awarding 1,738 RSUs and 8,775 stock options to two newly hired employees. The RSUs vest after three years, while stock options vest monthly over three years with a seven-year exercise term.
Lifecore Biomedical has signed a master services agreement with a new large global pharmaceutical customer to conduct development services and tech transfer for an injectable pharmaceutical product, potentially becoming a top five commercial customer.
Lifecore Biomedical will participate in three pharmaceutical industry conferences in October and November 2025, including PODD, CPHI Worldwide, and American Pharma Manufacturing & Outsourcing Summit, where they will host booth meetings and participate in panel discussions.
Law firm investigating potential claims against LifeCore Biomedical for alleged false financial statements and internal control deficiencies during October 2020 to March 2024 period.
Law firm investigating potential claims against LifeCore Biomedical for alleged false financial statements and internal control deficiencies during October 2020 to March 2024 period.
